From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Xu DH, Li Q, Hu H, et al. Transmembrane protein GRINA modulates aerobic glycolysis and promotes tumor progression in gastric cancer. J Exp Clin Cancer Res. 2018;37(1):308. doi:10.1186/s13046-018-0974-1
   PubMed Web of Science ®Google Scholar
• Zhang C, Chen Z, Chong X, et al. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. Clin Transl Med. 2020;10(8):e254. doi:10.1002/ctm2.254
   PubMed Web of Science ®Google Scholar
• Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–279. doi:10.3322/caac.21657
   PubMed Web of Science ®Google Scholar
• van der Veen A, Brenkman HJF, Seesing MFJ, et al. Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): a Multicenter Randomized Clinical Trial. J Clin Oncol. 2021;39(9):978–989. doi:10.1200/JCO.20.01540
   PubMed Web of Science ®Google Scholar
• Griffith DM, Li H, Werrett MV, Andrews PC, Sun H. Medicinal chemistry and biomedical applications of bismuth-based compounds and nanoparticles. Chem Soc Rev. 2021. doi:10.1039/d0cs00031k
   PubMed Web of Science ®Google Scholar
• Kang YK, Yook JH, Park YK, et al. PRODIGY: a Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021;39(26):2903–2913. doi:10.1200/JCO.20.02914
   PubMed Web of Science ®Google Scholar
• Cui J, Cui H, Yang M, et al. Tongue coating microbiome as a potential biomarker for gastritis including precancerous cascade. Protein Cell. 2019;10(7):496–509. doi:10.1007/s13238-018-0596-6
   PubMed Web of Science ®Google Scholar
• Hindson J. Nivolumab plus chemotherapy for advanced gastric cancer and oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):523. doi:10.1038/s41575-021-00484-8
   Google Scholar
• Meric-Bernstam F, Bahleda R, Hierro C, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 2021. doi:10.1158/2159-8290.CD-21-0697
   Web of Science ®Google Scholar
• Salas-Benito D, Perez-Gracia JL, Ponz-Sarvise M, et al. Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discov. 2021;11(6):1353–1367. doi:10.1158/2159-8290.CD-20-1312
   PubMed Web of Science ®Google Scholar
• Tarantino P, Modi S, Tolaney SM, et al. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: a Review. JAMA Oncol. 2021. doi:10.1001/jamaoncol.2021.3595
   PubMed Web of Science ®Google Scholar
• Yu J, Huang C, Sun Y, et al. Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: the CLASS-01 Randomized Clinical Trial. JAMA. 2019;321(20):1983–1992. doi:10.1001/jama.2019.5359
   PubMed Web of Science ®Google Scholar
• Liu F, Huang C, Xu Z, et al. Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: the CLASS02 Multicenter Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1590–1597. doi:10.1001/jamaoncol.2020.3152
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Miceli R, Raimondi A, et al. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol. 2019;37(35):3392–3400. doi:10.1200/JCO.19.01124
   PubMed Web of Science ®Google Scholar
• Yeoh KG, Tan P. Mapping the genomic diaspora of gastric cancer. Nat Rev Cancer. 2021. doi:10.1038/s41568-021-00412-7
   PubMed Web of Science ®Google Scholar
• Haffner I, Schierle K, Raimundez E, et al. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: results From the Prospective Multicenter VARIANZ Study. J Clin Oncol. 2021;39(13):1468–1478. doi:10.1200/JCO.20.02761
   PubMed Web of Science ®Google Scholar
• Roudko V, Bozkus CC, Orfanelli T, et al. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell. 2020;183(6):1634–1649 e1617. doi:10.1016/j.cell.2020.11.004
   PubMed Web of Science ®Google Scholar
• Chen ZH, Yan SM, Chen XX, et al. The genomic architecture of EBV and infected gastric tissue from precursor lesions to carcinoma. Genome Med. 2021;13(1):146. doi:10.1186/s13073-021-00963-2
   PubMed Web of Science ®Google Scholar
• Goutsouliak K, Veeraraghavan J, Sethunath V, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020;17(4):233–250. doi:10.1038/s41571-019-0299-9
   PubMed Web of Science ®Google Scholar
• Sareyeldin RM, Gupta I, Al-Hashimi I, et al. Gene Expression and miRNAs Profiling: function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer. Cancers. 2019;11:5. doi:10.3390/cancers11050646
   Web of Science ®Google Scholar
• Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341(6151):1192–1198. doi:10.1126/science.1241145
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Mezni E, Vicier C, Guerin M, Sabatier R, Bertucci F, Goncalves A. New Therapeutics in HER2-Positive Advanced Breast Cancer: towards a Change in Clinical Practices?pi. Cancers. 2020;12:6. doi:10.3390/cancers12061573
   Web of Science ®Google Scholar
• Menyhart O, Pongor LS, Gyorffy B. Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer. Front Pharmacol. 2018;9:1522. doi:10.3389/fphar.2018.01522
   PubMed Web of Science ®Google Scholar
• Yu C, Liu X, Yang J, et al. Combination of Immunotherapy With Targeted Therapy: theory and Practice in Metastatic Melanoma. Front Immunol. 2019;10:990. doi:10.3389/fimmu.2019.00990
   PubMed Web of Science ®Google Scholar
• Xu Y, Jiang J, Wang Y, et al. Engineered T Cell Therapy for Gynecologic Malignancies: challenges and Opportunities. Front Immunol. 2021;12:725330. doi:10.3389/fimmu.2021.725330
   PubMed Web of Science ®Google Scholar
• Terry RL, Meyran D, Fleuren EDG, et al. Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. Cancers. 2021;13:18. doi:10.3390/cancers13184704
   Web of Science ®Google Scholar
• Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. doi:10.1186/s12943-021-01428-1
   PubMed Web of Science ®Google Scholar
• Sun Y, Li F, Sonnemann H, et al. Evolution of CD8(+) T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer. Cells. 2021;10:9. doi:10.3390/cells10092379
   Web of Science ®Google Scholar
• Pan MR, Wu CC, Kan JY, et al. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers. 2019;12:1. doi:10.3390/cancers12010094
   PubMed Web of Science ®Google Scholar
• Geng L, Wang Z, Yang X, et al. Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. Theranostics. 2015;5(10):1154–1165. doi:10.7150/thno.12398
   PubMed Web of Science ®Google Scholar
• Cohen S. The epidermal growth factor (EGF). Cancer. 1983;51(10):1787–1791. doi:10.1002/1097-0142(19830515)51:10<1787::
   PubMed Web of Science ®Google Scholar
• Yu Y, Rishi AK, Turner JR, et al. Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR. Am J Physiol Cell Physiol. 2001;280(5):C1083–1089. doi:10.1152/ajpcell.2001.280.5.C1083
   PubMed Web of Science ®Google Scholar
• Huang F, Shi Q, Li Y, et al. HER2/EGFR-AKT Signaling Switches TGFbeta from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer. Cancer Res. 2018;78(21):6073–6085. doi:10.1158/0008-5472.CAN-18-0136
   PubMed Web of Science ®Google Scholar
• Quijano-Rubio A, Yeh HW, Park J, et al. De novo design of modular and tunable protein biosensors. Nature. 2021;591(7850):482–487. doi:10.1038/s41586-021-03258-z
   PubMed Web of Science ®Google Scholar
• Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem. 2015;84:739–764. doi:10.1146/annurev-biochem-060614-034402
   PubMed Web of Science ®Google Scholar
• Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008;26(10):1742–1751. doi:10.1200/JCO.2007.12.1178
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924):756–760. doi:10.1038/nature01392
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282–303. doi:10.1016/j.ccr.2014.02.025
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX. Ready to partner. Nat Struct Biol. 2003;10(3):158–159. doi:10.1038/nsb0303-158
   PubMedGoogle Scholar
• Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. doi:10.1016/j.phrs.2013.11.002
   PubMed Web of Science ®Google Scholar
• Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12(8):553–563. doi:10.1038/nrc3309
   PubMed Web of Science ®Google Scholar
• Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15(1):69–79. doi:10.1245/s10434-007-9596-0
   PubMed Web of Science ®Google Scholar
• Qi Z, Qiu Y, Wang Z, et al. A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma. Mol Oncol. 2021;15(4):1054–1068. doi:10.1002/1878-0261.12919
   PubMed Web of Science ®Google Scholar
• Chi A, Remick S, Tse W. EGFR inhibition in non-small cell lung cancer: current evidence and future directions. Biomark Res. 2013;1(1):2. doi:10.1186/2050-7771-1-2
   PubMedGoogle Scholar
• Arkhipov A, Shan Y, Kim ET, Dror RO, Shaw DE. Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. Elife. 2013;2:e00708. doi:10.7554/eLife.00708
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang F, Niu R. Functions of Shp2 in cancer. J Cell Mol Med. 2015;19(9):2075–2083. doi:10.1111/jcmm.12618
   PubMed Web of Science ®Google Scholar
• Katona BW, Rustgi AK. Gastric Cancer Genomics: advances and Future Directions. Cell Mol Gastroenterol Hepatol. 2017;3(2):211–217. doi:10.1016/j.jcmgh.2017.01.003
   PubMed Web of Science ®Google Scholar
• Tegtmeyer N, Harrer A, Rottner K, Backert S. Helicobacter pylori CagA Induces Cortactin Y-470 Phosphorylation-Dependent Gastric Epithelial Cell Scattering via Abl, Vav2 and Rac1 Activation. Cancers. 2021;13(16):5498. doi:10.3390/cancers13164241
   PubMed Web of Science ®Google Scholar
• Wang M, Chen L, Chen Y, et al. Intracellular matrix Gla protein promotes tumor progression by activating JAK2/STAT5 signaling in gastric cancer. Mol Oncol. 2020;14(5):1045–1058. doi:10.1002/1878-0261.12652
   PubMed Web of Science ®Google Scholar
• Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10(11):643–655. doi:10.1038/nrclinonc.2013.170
   PubMed Web of Science ®Google Scholar
• Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12:S3–8. doi:10.1093/annonc/12.suppl_1.s3
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004;319(1):1–11. doi:10.1016/j.bbrc.2004.04.150
   PubMed Web of Science ®Google Scholar
• Nam HJ, Im SA, Oh DY, et al. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther. 2013;12(1):16–26. doi:10.1158/1535-7163.MCT-12-0109
   PubMed Web of Science ®Google Scholar
• Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol. 2009;135(10):1331–1339. doi:10.1007/s00432-009-0574-8
   PubMed Web of Science ®Google Scholar
• Su CC. Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway. Int J Mol Med. 2018;41(4):2389–2396. doi:10.3892/ijmm.2018.3407
   PubMed Web of Science ®Google Scholar
• Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;284(1):54–65. doi:10.1016/s0014-4827(02)00101-5
   PubMed Web of Science ®Google Scholar
• Kaumaya PT, Foy KC. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 2012;8(8):961–987. doi:10.2217/fon.12.95
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Ikehara Y, Kodera Y, et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer. 2006;95(11):1504–1513. doi:10.1038/sj.bjc.6603459
   PubMed Web of Science ®Google Scholar
• Jenke R, Holzhauser-Rein M, Mueller-Wilke S, Lordick F, Aigner A, Buch T. SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells. Int J Mol Sci. 2020;22(1):155. doi:10.3390/ijms22010082
   PubMed Web of Science ®Google Scholar
• Fukuda K, Funakoshi T. Metastatic Extramammary Paget’s Disease: pathogenesis and Novel Therapeutic Approach. Front Oncol. 2018;8:38. doi:10.3389/fonc.2018.00038
   PubMed Web of Science ®Google Scholar
• Jabbour E, Ottmann OG, Deininger M, Hochhaus A. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica. 2014;99(1):7–18. doi:10.3324/haematol.2013.087171
   PubMed Web of Science ®Google Scholar
• Mezynski MJ, Farrelly AM, Cremona M, et al. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. J Transl Med. 2021;19(1):184. doi:10.1186/s12967-021-02842-1
   PubMed Web of Science ®Google Scholar
• Han ME, Kim HJ, Shin DH, Hwang SH, Kang CD, Oh SO. Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells. J Gastroenterol. 2015;50(6):645–656. doi:10.1007/s00535-014-1008-1
   PubMed Web of Science ®Google Scholar
• Ishii K, Morii N, Yamashiro H. Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evid. 2019;14:51–70. doi:10.2147/CE.S217848
   PubMed Web of Science ®Google Scholar
• Ryu MH, Yoo C, Kim JG, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer. 2015;51(4):482–488. doi:10.1016/j.ejca.2014.12.015
   PubMed Web of Science ®Google Scholar
• Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372–1384. doi:10.1016/S1470-2045(18)30481-9
   PubMed Web of Science ®Google Scholar
• Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol. 2011;22(12):2610–2615. doi:10.1093/annonc/mdr021
   PubMed Web of Science ®Google Scholar
• Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: tyTAN–a randomized, phase III study. J Clin Oncol. 2014;32(19):2039–2049. doi:10.1200/JCO.2013.53.6136
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC–A Randomized Phase III Trial. J Clin Oncol. 2016;34(5):443–451. doi:10.1200/JCO.2015.62.6598
   PubMed Web of Science ®Google Scholar
• De Pauw I, Wouters A, Van den Bossche J, et al. Preclinical and clinical studies on Afatinib in monotherapy and in combination regimens: potential impact in colorectal cancer. Pharmacol Ther. 2016;166:71–83. doi:10.1016/j.pharmthera.2016.06.014
   PubMed Web of Science ®Google Scholar
• Deeks ED. Neratinib: first Global Approval. Drugs. 2017;77(15):1695–1704. doi:10.1007/s40265-017-0811-4
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–653. doi:10.1016/S1470-2045(17)30111-0
   PubMed Web of Science ®Google Scholar
• Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, Phase 1 study. Lancet Oncol. 2019;20(6):827–836. doi:10.1016/S1470-2045(19)30088-9
   PubMed Web of Science ®Google Scholar
• Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124–1135. doi:10.1016/S1470-2045(19)30328-6
   PubMed Web of Science ®Google Scholar
• Barok M, Le Joncour V, Martins A, et al. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer Lett. 2020;473:156–163. doi:10.1016/j.canlet.2019.12.037
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F. ZW25 Effective in HER2-Positive Cancers. Cancer Discov. 2019;9(1):8. doi:10.1158/2159-8290.CD-NB2018-162
   Web of Science ®Google Scholar
• de Vries Schultink AHM, Bol K, Doornbos RP, et al. Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors. Clin Pharmacokinet. 2020;59(7):875–884. doi:10.1007/s40262-020-00858-2
   PubMed Web of Science ®Google Scholar
• Kirouac DC, Du JY, Lahdenranta J, et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal. 2013;6(288):ra68. doi:10.1126/scisignal.2004008
   PubMed Web of Science ®Google Scholar
• Yang YM, Hong P, Xu WW, He QY, Li B. Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020;5(1):229. doi:10.1038/s41392-020-00323-3
   PubMed Web of Science ®Google Scholar
• Van cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–484. doi:10.1007/s10120-014-0402-y
   PubMed Web of Science ®Google Scholar
• An E, Ock CY, Kim TY, et al. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Ann Oncol. 2017;28(1):110–115. doi:10.1093/annonc/mdw442
   PubMed Web of Science ®Google Scholar
• Wang DS, Liu ZX, Lu YX, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019;68(7):1152–1161. doi:10.1136/gutjnl-2018-316522
   PubMed Web of Science ®Google Scholar
• Okines AFC, Turner NC. Heterogeneous HER2 Amplification-a New Clinical Category of HER2-Positive Breast Cancer? Cancer Discov. 2021;11(10):2369–2371. doi:10.1158/2159-8290.CD-21-0936
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, King KE, Mohan N, Endo Y, Wu WJ. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab. Expert Opin Drug Metab Toxicol. 2017;13(7):755–766. doi:10.1080/17425255.2017.1337746
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127–137. doi:10.1016/s1535-6108(02)00097-1
   PubMed Web of Science ®Google Scholar
• Gleeson JP, Keegan NM, Morris PG. Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer. Expert Opin Biol Ther. 2018;18(3):251–262. doi:10.1080/14712598.2018.1410132
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. doi:10.1056/NEJMoa1413513
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol. 2010;7(2):98–107. doi:10.1038/nrclinonc.2009.216
   PubMed Web of Science ®Google Scholar
• Bilancia D, Rosati G, Dinota A, Germano D, Romano R, Manzione L. Lapatinib in breast cancer. Ann Oncol. 2007;18(Suppl 6):vi26–30. doi:10.1093/annonc/mdm220
   PubMed Web of Science ®Google Scholar
• Jiao XD, Ding C, Zang YS, Yu G. Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report. BMC Cancer. 2018;18(1):206. doi:10.1186/s12885-018-4116-0
   PubMed Web of Science ®Google Scholar
• Voigtlaender M, Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res. 2018;211:19–44. doi:10.1007/978-3-319-91442-8_2
   PubMedGoogle Scholar
• LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17(20):6437–6447. doi:10.1158/1078-0432.CCR-11-0762
   PubMed Web of Science ®Google Scholar
• Griguolo G, Braso-Maristany F, Gonzalez-Farre B, et al. ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Cancers. 2020;12:7. doi:10.3390/cancers12071902
   Web of Science ®Google Scholar
• Jhaveri KL, Wang XV, Makker V, et al. Ado-Trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019;30(11):1821–1830. doi:10.1093/annonc/mdz291
   PubMed Web of Science ®Google Scholar
• Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48. doi:10.1038/s41571-019-0268-3
   PubMed Web of Science ®Google Scholar
• Le Joncour V, Martins A, Puhka M, et al. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. Mol Cancer Ther. 2019;18(10):1721–1730. doi:10.1158/1535-7163.MCT-19-0207
   PubMed Web of Science ®Google Scholar
• Menderes G, Bonazzoli E, Bellone S, et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res. 2017;23(19):5836–5845. doi:10.1158/1078-0432.CCR-16-2862
   PubMed Web of Science ®Google Scholar
• Skidmore L, Sakamuri S, Knudsen NA, et al. ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers. Mol Cancer Ther. 2020;19(9):1833–1843. doi:10.1158/1535-7163.MCT-19-1004
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. doi:10.1038/s41573-019-0028-1
   PubMed Web of Science ®Google Scholar
• de Vries Schultink AHM, Doornbos RP, Bakker ABH, et al. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose. Invest New Drugs. 2018;36(6):1006–1015. doi:10.1007/s10637-018-0593-x
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F. MCLA-128 Fights NRG1 Fusion-Positive Cancers. Cancer Discov. 2019;9(12):1636. doi:10.1158/2159-8290.CD-NB2019-128
   Web of Science ®Google Scholar
• Yu S, Liu Q, Han X, et al. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Exp Hematol Oncol. 2017;6:31. doi:10.1186/s40164-017-0091-4
   PubMed Web of Science ®Google Scholar
• McDonagh CF, Huhalov A, Harms BD, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther. 2012;11(3):582–593. doi:10.1158/1535-7163.MCT-11-0820
   PubMed Web of Science ®Google Scholar
• Liu D, Zhao J, Song Y. Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol. 2019;12(1):69. doi:10.1186/s13045-019-0763-0
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024–10028. doi:10.1073/pnas.86.24.10024
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–724. doi:10.1073/pnas.90.2.720
   PubMed Web of Science ®Google Scholar
• Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol. 1998;161(6):2791–2797.
   PubMed Web of Science ®Google Scholar
• Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004;172(1):104–113. doi:10.4049/jimmunol.172.1.104
   PubMed Web of Science ®Google Scholar
• Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S, Paulos CM. CAR T Cells in Solid Tumors: blueprints for Building Effective Therapies. Front Immunol. 2018;9:1740. doi:10.3389/fimmu.2018.01740
   PubMed Web of Science ®Google Scholar
• Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. 2017;10(1):94. doi:10.1186/s13045-017-0453-8
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–1415. doi:10.1016/S1470-2045(21)00375-2
   PubMed Web of Science ®Google Scholar
• Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. J Clin Oncol. 2020;38(17):1938–1950. doi:10.1200/JCO.19.03279
   PubMed Web of Science ®Google Scholar
• Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020;38(32):3794–3804. doi:10.1200/JCO.20.01342
   PubMed Web of Science ®Google Scholar
• Yao S, Jianlin C, Yarong L, et al. Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML. Front Oncol. 2019;9:1358. doi:10.3389/fonc.2019.01358
   PubMed Web of Science ®Google Scholar
• Lin S, Cheng L, Ye W, et al. Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86-Positive B Cell Malignancies. Front Immunol. 2021;12:642528. doi:10.3389/fimmu.2021.642528
   PubMed Web of Science ®Google Scholar
• Wenthe J, Naseri S, Labani-Motlagh A, et al. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. Cancer Immunol Immunother. 2021;70(10):2851–2865. doi:10.1007/s00262-021-02895-7
   PubMed Web of Science ®Google Scholar
• Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4(3):e994446. doi:10.4161/2162402X.2014.994446
   PubMed Web of Science ®Google Scholar
• Cui J, Wang H, Medina R, et al. Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma. Cancers. 2020;12(1):87. doi:10.3390/cancers12010139
   Web of Science ®Google Scholar
• Li H, Ding J, Lu M, et al. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models. J Immunother. 2020;43(1):16–28. doi:10.1097/CJI.0000000000000301
   PubMed Web of Science ®Google Scholar
• Ghorashian S, Kramer AM, Onuoha S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408–1414. doi:10.1038/s41591-019-0549-5
   PubMed Web of Science ®Google Scholar
• Myers RM, Taraseviciute A, Steinberg SM, et al. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. J Clin Oncol. 2021:JCO2101405. doi:10.1200/JCO.21.01405
   Web of Science ®Google Scholar
• Meric-Bernstam F. CAR Linker Length Modulates CD22-Targeted CAR T-cell Efficacy in ALL. Cancer Discov. 2021;11(7):1611. doi:10.1158/2159-8290.CD-RW2021-065
   Web of Science ®Google Scholar
• Bueno C, Velasco-Hernandez T, Gutierrez-Aguera F, et al. CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. Leukemia. 2019;33(8):2090–2125. doi:10.1038/s41375-019-0418-8
   PubMed Web of Science ®Google Scholar
• Dai H, Tong C, Shi D, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020;9(1):1846926. doi:10.1080/2162402X.2020.1846926
   PubMed Web of Science ®Google Scholar
• Han Y, Sun B, Cai H, Xuan Y. Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy. Cancer Immunol Immunother. 2021;70(10):2795–2803. doi:10.1007/s00262-021-02891-x
   PubMed Web of Science ®Google Scholar
• Vora P, Venugopal C, Salim SK, et al. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 2020;26(6):832–844 e836. doi:10.1016/j.stem.2020.04.008
   PubMed Web of Science ®Google Scholar
• Van Laethem F, Saba I, Lu J, et al. Novel MHC-Independent alphabetaTCRs Specific for CD48, CD102, and CD155 Self-Proteins and Their Selection in the Thymus. Front Immunol. 2020;11:1216. doi:10.3389/fimmu.2020.01216
   PubMed Web of Science ®Google Scholar
• Katz SC, Moody AE, Guha P, et al. HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery. J Immunother Cancer. 2020;8(2):158. doi:10.1136/jitc-2020-001097
   Web of Science ®Google Scholar
• Kumar J, Kumar R, Kumar Singh A, et al. Deletion of Cbl-b inhibits CD8(+) T-cell exhaustion and promotes CAR T-cell function. J Immunother Cancer. 2021;9(1):215. doi:10.1136/jitc-2020-001688
   Web of Science ®Google Scholar
• Zhang C, Wang Z, Yang Z, et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA(+) Metastatic Colorectal Cancers. Mol Ther. 2017;25(5):1248–1258. doi:10.1016/j.ymthe.2017.03.010
   PubMed Web of Science ®Google Scholar
• Zhang E, Yang P, Gu J, et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018;11(1):102. doi:10.1186/s13045-018-0646-9
   PubMed Web of Science ®Google Scholar
• Jiang H, Shi Z, Wang P, et al. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. J Natl Cancer Inst. 2019;111(4):409–418. doi:10.1093/jnci/djy134
   PubMedGoogle Scholar
• Luo H, Su J, Sun R, et al. Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion. Clin Cancer Res. 2020;26(20):5494–5505. doi:10.1158/1078-0432.CCR-20-0777
   PubMed Web of Science ®Google Scholar
• Zhu G, Foletti D, Liu X, et al. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Sci Rep. 2019;9(1):8420. doi:10.1038/s41598-019-44874-0
   PubMed Web of Science ®Google Scholar
• Klar AS, Gopinadh J, Kleber S, Wadle A, Renner C. Treatment with 5-Aza-2’-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing. PLoS One. 2015;10(10):e0139221. doi:10.1371/journal.pone.0139221
   PubMed Web of Science ®Google Scholar
• Hegde M, Joseph SK, Pashankar F, et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020;11(1):3549. doi:10.1038/s41467-020-17175-8
   PubMed Web of Science ®Google Scholar
• Vitanza NA, Johnson AJ, Wilson AL, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med. 2021;27(9):1544–1552. doi:10.1038/s41591-021-01404-8
   PubMed Web of Science ®Google Scholar
• Xia L, Zheng Z, Liu JY, et al. Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition. Cancer Immunol Res. 2021;9(6):707–722. doi:10.1158/2326-6066.CIR-20-0405
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhu X, Wei X, Tang C, Zhang W. HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188549. doi:10.1016/j.bbcan.2021.188549
   PubMed Web of Science ®Google Scholar
• Maggs L, Cattaneo G, Dal AE, Moghaddam AS, Ferrone S. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. Front Neurosci. 2021;15:662064. doi:10.3389/fnins.2021.662064
   PubMed Web of Science ®Google Scholar
• Huang SL, Wang YM, Wang QY, et al. Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy. Front Genet. 2021;12:691391. doi:10.3389/fgene.2021.691391
   PubMed Web of Science ®Google Scholar
• Maiti A, Daver NG. Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia. Clin Cancer Res. 2021;27(21):5739–5741. doi:10.1158/1078-0432.CCR-21-2574
   PubMed Web of Science ®Google Scholar
• Bughda R, Dimou P, D’Souza RR, Klampatsa A. Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: launching an Attack on Tumor Stroma. Immunotargets Ther. 2021;10:313–323. doi:10.2147/ITT.S291767
   PubMed Web of Science ®Google Scholar
• Lo A, Wang LS, Scholler J, et al. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res. 2015;75(14):2800–2810. doi:10.1158/0008-5472.CAN-14-3041
   PubMed Web of Science ®Google Scholar
• Kim M, Pyo S, Kang CH, et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS One. 2018;13(6):e0198347. doi:10.1371/journal.pone.0198347
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Powell DJ Jr, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med. 2012;10:157. doi:10.1186/1479-5876-10-157
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Poussin M, Chacon JA, Figini M, Powell DJ Jr. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol. 2016;9(1):56. doi:10.1186/s13045-016-0285-y
   PubMed Web of Science ®Google Scholar
• Moghimi B, Muthugounder S, Jambon S, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun. 2021;12(1):511. doi:10.1038/s41467-020-20785-x
   PubMed Web of Science ®Google Scholar
• Yu J, Wu X, Yan J, et al. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. J Hematol Oncol. 2018;11(1):1. doi:10.1186/s13045-017-0548-2
   PubMed Web of Science ®Google Scholar
• Meng M, Wu YC. Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma. J Immunol Res. 2021;2021:1782728. doi:10.1155/2021/1782728
   PubMed Web of Science ®Google Scholar
• Pang N, Shi J, Qin L, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14(1):118. doi:10.1186/s13045-021-01128-9
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley VS, Hegde M, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015;33(15):1688–1696. doi:10.1200/JCO.2014.58.0225
   PubMed Web of Science ®Google Scholar
• Nellan A, Rota C, Majzner R, et al. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer. 2018;6(1):30. doi:10.1186/s40425-018-0340-z
   PubMed Web of Science ®Google Scholar
• Song Y, Tong C, Wang Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9(10):867–878. doi:10.1007/s13238-017-0384-8
   PubMed Web of Science ®Google Scholar
• Szoor A, Toth G, Zsebik B, et al. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 2020;484:1–8. doi:10.1016/j.canlet.2020.04.008
   PubMed Web of Science ®Google Scholar
• Teng R, Zhao J, Zhao Y, et al. Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model. J Immunother. 2019;42(2):33–42. doi:10.1097/CJI.0000000000000251
   PubMed Web of Science ®Google Scholar
• Terlikowska KM, Dobrzycka B, Terlikowski SJ. Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. Int J Mol Sci. 2021;22(7):658. doi:10.3390/ijms22073495
   PubMed Web of Science ®Google Scholar
• Boice M, Salloum D, Mourcin F, et al. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell. 2016;167(2):405–418 e413. doi:10.1016/j.cell.2016.08.032
   PubMed Web of Science ®Google Scholar
• Jung M, Yang Y, McCloskey JE, et al. Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Mol Ther Oncolytics. 2020;18:587–601. doi:10.1016/j.omto.2020.08.009
   PubMed Web of Science ®Google Scholar
• Wei H, Wang Z, Kuang Y, et al. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer. Front Immunol. 2020;11:573823. doi:10.3389/fimmu.2020.573823
   PubMed Web of Science ®Google Scholar
• Pituch KC, Miska J, Krenciute G, et al. Adoptive Transfer of IL13Ralpha2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Mol Ther. 2018;26(4):986–995. doi:10.1016/j.ymthe.2018.02.001
   PubMed Web of Science ®Google Scholar
• Hong H, Stastny M, Brown C, et al. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J Immunother. 2014;37(2):93–104. doi:10.1097/CJI.0000000000000018
   PubMed Web of Science ®Google Scholar
• Kunkele A, Taraseviciute A, Finn LS, et al. Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility. Clin Cancer Res. 2017;23(2):466–477. doi:10.1158/1078-0432.CCR-16-0354
   PubMed Web of Science ®Google Scholar
• Tang L, Yang J, Liu W, et al. Liver sinusoidal endothelial cell lectin, LSECtin, negatively regulates hepatic T-cell immune response. Gastroenterology. 2009;137(4):1498–1508 e1491-1495. doi:10.1053/j.gastro.2009.07.051
   Web of Science ®Google Scholar
• Montemagno C, Cassim S, Pouyssegur J, Broisat A, Pages G. From Malignant Progression to Therapeutic Targeting: current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci. 2020;21(11):32. doi:10.3390/ijms21114067
   Web of Science ®Google Scholar
• Schoutrop E, El-Serafi I, Poiret T, et al. Mesothelin-Specific CAR T Cells Target Ovarian Cancer. Cancer Res. 2021;81(11):3022–3035. doi:10.1158/0008-5472.CAN-20-2701
   PubMed Web of Science ®Google Scholar
• Yeo D, Castelletti L, van Zandwijk N, Rasko JEJ. Hitting the Bull’s-Eye: mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma. Cancers. 2021;13(16):14. doi:10.3390/cancers13163932
   Web of Science ®Google Scholar
• Supimon K, Sangsuwannukul T, Sujjitjoon J, et al. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Sci Rep. 2021;11(1):6276. doi:10.1038/s41598-021-85747-9
   PubMed Web of Science ®Google Scholar
• You F, Jiang L, Zhang B, et al. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci. 2016;59(4):386–397. doi:10.1007/s11427-016-5024-7
   PubMed Web of Science ®Google Scholar
• Han Y, Xie W, Song DG, Powell DJ Jr. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 2018;11(1):92. doi:10.1186/s13045-018-0635-z
   PubMed Web of Science ®Google Scholar
• He C, Zhou Y, Li Z, et al. Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion. Cancers. 2020;12(7):54987. doi:10.3390/cancers12071969
   Web of Science ®Google Scholar
• Zhang Y, Li X, Zhang J, Mao L. Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer. Biomed Pharmacother. 2020;131:110562. doi:10.1016/j.biopha.2020.110562
   PubMed Web of Science ®Google Scholar
• Liu M, Wang X, Li W, et al. Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis. 2020;9(8):72. doi:10.1038/s41389-020-00257-z
   PubMed Web of Science ®Google Scholar
• Nelson MA, Ngamcherdtrakul W, Luoh SW, Yantasee W. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer. Cancer Metastasis Rev. 2021;40(2):519–536. doi:10.1007/s10555-021-09968-0
   PubMed Web of Science ®Google Scholar
• Zhao W, Jia L, Zhang M, et al. The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer. Am J Cancer Res. 2019;9(8):1846–1856.
   PubMed Web of Science ®Google Scholar
• Priceman SJ, Gerdts EA, Tilakawardane D, et al. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology. 2018;7(2):e1380764. doi:10.1080/2162402X.2017.1380764
   PubMed Web of Science ®Google Scholar
• Wu D, Lv J, Zhao R, et al. PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomark Res. 2020;8:3. doi:10.1186/s40364-020-0183-x
   PubMed Web of Science ®Google Scholar
• Wang G, Zhou X, Fuca G, et al. Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors. J Immunother Cancer. 2021;9(4):548. doi:10.1136/jitc-2020-002173
   Web of Science ®Google Scholar
• Zuccolotto G, Penna A, Fracasso G, et al. PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”. Front Oncol. 2021;11:708073. doi:10.3389/fonc.2021.708073
   PubMed Web of Science ®Google Scholar
• Katz SC, Burga RA, McCormack E, et al. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. Clin Cancer Res. 2015;21(14):3149–3159. doi:10.1158/1078-0432.CCR-14-1421
   PubMed Web of Science ®Google Scholar
• Tchou J, Zhao Y, Levine BL, et al. Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer Immunol Res. 2017;5(12):1152–1161. doi:10.1158/2326-6066.CIR-17-0189
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z, Ding Y, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2021;147(12):3725–3734. doi:10.1007/s00432-021-03613-7
   PubMed Web of Science ®Google Scholar
• Liu Y, Guo Y, Wu Z, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy. 2020;22(10):573–580. doi:10.1016/j.jcyt.2020.04.088
   PubMed Web of Science ®Google Scholar
• Hiltbrunner S, Britschgi C, Schuberth P, et al. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial. Ann Oncol. 2021;32(1):120–121. doi:10.1016/j.annonc.2020.10.474
   PubMed Web of Science ®Google Scholar
• Junghans RP, Ma Q, Rathore R, et al. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate. 2016;76(14):1257–1270. doi:10.1002/pros.23214
   PubMed Web of Science ®Google Scholar
• Feng K, Liu Y, Guo Y, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2018;9(10):838–847. doi:10.1007/s13238-017-0440-4
   PubMed Web of Science ®Google Scholar
• Chen YJ, You ML, Chong QY, et al. Autocrine Human Growth Hormone Promotes Invasive and Cancer Stem Cell-Like Behavior of Hepatocellular Carcinoma Cells by STAT3 Dependent Inhibition of CLAUDIN-1 Expression. Int J Mol Sci. 2017;18(6):54. doi:10.3390/ijms18061274
   Web of Science ®Google Scholar
• Bebnowska D, Grywalska E, Niedzwiedzka-Rystwej P, et al. CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer. J Clin Med. 2020;9(6):14. doi:10.3390/jcm9061894
   Web of Science ®Google Scholar
• Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, Tureci O. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol. 2019;49(9):870–876. doi:10.1093/jjco/hyz068
   PubMed Web of Science ®Google Scholar
• Wen Y, Graybill WS, Previs RA, et al. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015;21(2):448–459. doi:10.1158/1078-0432.CCR-14-1578
   PubMed Web of Science ®Google Scholar
• Ma DW, Finnell RH, Davidson LA, et al. Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Res. 2005;65(3):887–897.
   PubMed Web of Science ®Google Scholar
• Shivange G, Urbanek K, Przanowski P, et al. A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. Cancer Cell. 2018;34(2):331–345 e311. doi:10.1016/j.ccell.2018.07.005
   PubMed Web of Science ®Google Scholar
• Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619–626. doi:10.1016/j.ygyno.2007.11.020
   PubMed Web of Science ®Google Scholar
• Zuo S, Wen Y, Panha H, et al. Modification of cytokine-induced killer cells with folate receptor alpha (FRalpha)-specific chimeric antigen receptors enhances their antitumor immunity toward FRalpha-positive ovarian cancers. Mol Immunol. 2017;85:293–304. doi:10.1016/j.molimm.2017.03.017
   PubMed Web of Science ®Google Scholar
• van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med (Berl). 1996;74(1):13–33. doi:10.1007/BF00202069
   PubMed Web of Science ®Google Scholar
• Ziprin P, Ridgway PF, Pfistermuller KL, Peck DH, Darzi AW. ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: a potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes. 2003;10(3):141–154.
   PubMed Web of Science ®Google Scholar
• Jung WC, Jang YJ, Kim JH, et al. Expression of intercellular adhesion molecule-1 and e-selectin in gastric cancer and their clinical significance. J Gastric Cancer. 2012;12(3):140–148. doi:10.5230/jgc.2012.12.3.140
   PubMedGoogle Scholar
• Min IM, Shevlin E, Vedvyas Y, et al. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors. Clin Cancer Res. 2017;23(24):7569–7583. doi:10.1158/1078-0432.CCR-17-2008
   PubMed Web of Science ®Google Scholar
• Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93(1):136–140. doi:10.1073/pnas.93.1.136
   PubMed Web of Science ®Google Scholar
• Lv J, Zhao R, Wu D, et al. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019;12(1):18. doi:10.1186/s13045-019-0704-y
   PubMed Web of Science ®Google Scholar
• Sotoudeh M, Shirvani SI, Merat S, Ahmadbeigi N, Naderi M. MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. J Cell Biochem. 2019;120(4):5010–5017. doi:10.1002/jcb.27776
   PubMed Web of Science ®Google Scholar
• Beatty GL, O’Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps. Pharmacol Ther. 2016;166:30–39. doi:10.1016/j.pharmthera.2016.06.010
   PubMed Web of Science ®Google Scholar
• Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted CARs: driving T Cells to Solid Tumors. Cancer Discov. 2016;6(2):133–146. doi:10.1158/2159-8290.CD-15-0583
   PubMed Web of Science ®Google Scholar
• Watanabe K, Luo Y, Da T, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018;3(7):75. doi:10.1172/jci.insight.99573
   Web of Science ®Google Scholar
• Zhang Q, Liu G, Liu J, et al. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice. Mol Ther Oncolytics. 2021;20:556–568. doi:10.1016/j.omto.2021.02.013
   PubMed Web of Science ®Google Scholar
• Zhao R, Cui Y, Zheng Y, et al. Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer. Front Immunol. 2021;12:660488. doi:10.3389/fimmu.2021.660488
   PubMed Web of Science ®Google Scholar
• Stojanovic A, Correia MP, Cerwenka A. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease. Front Immunol. 2018;9:827. doi:10.3389/fimmu.2018.00827
   PubMed Web of Science ®Google Scholar
• Basu S, Eriksson M, Pioli PA, et al. Human uterine NK cells interact with uterine macrophages via NKG2D upon stimulation with PAMPs. Am J Reprod Immunol. 2009;61(1):52–61. doi:10.1111/j.1600-0897.2008.00661.x
   PubMed Web of Science ®Google Scholar
• Spear P, Wu MR, Sentman ML, Sentman CL. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8.
   PubMedGoogle Scholar
• Baumeister SH, Murad J, Werner L, et al. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019;7(1):100–112. doi:10.1158/2326-6066.CIR-18-0307
   PubMed Web of Science ®Google Scholar
• Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. Cancer Res. 2018;78(4):1031–1043. doi:10.1158/0008-5472.CAN-17-1788
   PubMed Web of Science ®Google Scholar
• Sun B, Yang D, Dai H, et al. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells. Cancer Immunol Res. 2019;7(11):1813–1823. doi:10.1158/2326-6066.CIR-19-0026
   PubMed Web of Science ®Google Scholar
• Tao K, He M, Tao F, et al. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment. Cancer Chemother Pharmacol. 2018;82(5):815–827. doi:10.1007/s00280-018-3670-0
   PubMed Web of Science ®Google Scholar
• de Vries NL, Swets M, Vahrmeijer AL, Hokland M, Kuppen PJ. The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. Int J Mol Sci. 2016;17:7. doi:10.3390/ijms17071030
   Web of Science ®Google Scholar
• Jiang W, Pan S, Chen X, Wang ZW, Zhu X. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy. Mol Cancer. 2021;20(1):116. doi:10.1186/s12943-021-01406-7
   PubMed Web of Science ®Google Scholar
• Gong B, Kiyotani K, Sakata S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;216(4):982–1000. doi:10.1084/jem.20180870
   PubMed Web of Science ®Google Scholar
• Yu H, Chen P, Xia L, et al. PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer. J Immunother Cancer. 2021;9:11. doi:10.1136/jitc-2021-003431
   Web of Science ®Google Scholar
• Yang Y, Zhang X, Lin F, et al. Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells. J Hematol Oncol. 2019;12(1):46. doi:10.1186/s13045-019-0723-8
   PubMed Web of Science ®Google Scholar
• Li Q, Zhou ZW, Lu J, et al. PD-L1(P146R) is prognostic and a negative predictor of response to immunotherapy in gastric cancer. Mol Ther. 2021. doi:10.1016/j.ymthe.2021.09.013
   Web of Science ®Google Scholar
• Kobold S, Grassmann S, Chaloupka M, et al. Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy. J Natl Cancer Inst. 2015;107:8. doi:10.1093/jnci/djv146
   Google Scholar
• Schlenker R, Olguin-Contreras LF, Leisegang M, et al. Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. Cancer Res. 2017;77(13):3577–3590. doi:10.1158/0008-5472.CAN-16-1922
   PubMed Web of Science ®Google Scholar
• Qin L, Zhao R, Chen D, et al. Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomark Res. 2020;8:19. doi:10.1186/s40364-020-00198-0
   PubMed Web of Science ®Google Scholar
• Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res. 2010;16(14):3533–3538. doi:10.1158/1078-0432.CCR-09-3169
   PubMed Web of Science ®Google Scholar
• Wei X, Lai Y, Li J, et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017;6(3):e1284722. doi:10.1080/2162402X.2017.1284722
   PubMed Web of Science ®Google Scholar
• Weimin S, Abula A, Qianghong D, Wenguang W. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. Cancer Biol Ther. 2020;21(6):570–580. doi:10.1080/15384047.2020.1739952
   PubMed Web of Science ®Google Scholar
• Kloss CC, Lee J, Zhang A, et al. Dominant-Negative TGF-beta Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther. 2018;26(7):1855–1866. doi:10.1016/j.ymthe.2018.05.003
   PubMed Web of Science ®Google Scholar
• Bai C, Gao S, Hu S, et al. Self-Assembled Multivalent Aptamer Nanoparticles with Potential CAR-like Characteristics Could Activate T Cells and Inhibit Melanoma Growth. Mol Ther Oncolytics. 2020;17:9–20. doi:10.1016/j.omto.2020.03.002
   PubMed Web of Science ®Google Scholar
• Maher J, Wilkie S, Davies DM, et al. Targeting of Tumor-Associated Glycoforms of MUC1 with CAR T Cells. Immunity. 2016;45(5):945–946. doi:10.1016/j.immuni.2016.10.014
   PubMed Web of Science ®Google Scholar
• Wang HF, Wang SS, Huang MC, Liang XH, Tang YJ, Tang YL. Targeting Immune-Mediated Dormancy: a Promising Treatment of Cancer. Front Oncol. 2019;9:498. doi:10.3389/fonc.2019.00498
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev. 2014;257(1):91–106. doi:10.1111/imr.12126
   PubMed Web of Science ®Google Scholar
• Yu S, Li A, Liu Q, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78. doi:10.1186/s13045-017-0444-9
   PubMed Web of Science ®Google Scholar
• Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566–581. doi:10.1038/nrc.2016.97
   PubMed Web of Science ®Google Scholar
• Caruana I, Diaconu I, Dotti G. From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. Semin Oncol. 2014;41(5):661–666. doi:10.1053/j.seminoncol.2014.08.005
   PubMed Web of Science ®Google Scholar
• Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036–3052. doi:10.1172/JCI83416
   PubMed Web of Science ®Google Scholar
• Quintarelli C, Guercio M, Manni S, et al. Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. J Immunother Cancer. 2021;9(6). doi:10.1136/jitc-2020-001514
   Web of Science ®Google Scholar
• Salguero-Aranda C, Amaral AT, Olmedo-Pelayo J, Diaz-Martin J, Alava E. Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape. Cells. 2020;9:4. doi:10.3390/cells9040804
   Web of Science ®Google Scholar
• Li C, Shen Q, Zhang P, et al. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells. J Exp Clin Cancer Res. 2021;40(1):315. doi:10.1186/s13046-021-02120-4
   PubMed Web of Science ®Google Scholar
• Shi J, Li F, Yao X, et al. The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. Oncogene. 2018;37(22):3022–3038. doi:10.1038/s41388-018-0204-5
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang G, Ma Z, et al. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Nat Commun. 2021;12(1):2812. doi:10.1038/s41467-021-23053-8
   PubMed Web of Science ®Google Scholar
• Yu S, Hu C, Cai L, et al. Seven-Gene Signature Based on Glycolysis Is Closely Related to the Prognosis and Tumor Immune Infiltration of Patients With Gastric Cancer. Front Oncol. 2020;10:1778. doi:10.3389/fonc.2020.01778
   PubMed Web of Science ®Google Scholar
• Sawaisorn P, Atjanasuppat K, Anurathapan U, Chutipongtanate S, Hongeng S. Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. Vaccines. 2020;8:4. doi:10.3390/vaccines8040753
   Web of Science ®Google Scholar
• Thadi A, Khalili M, Morano WF, Richard SD, Katz SC, Bowne WB. Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. Vaccines. 2018;6:3. doi:10.3390/vaccines6030054
   Web of Science ®Google Scholar
• Zhao D, Klempner SJ, Chao J. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. J Hematol Oncol. 2019;12(1):50. doi:10.1186/s13045-019-0737-2
   PubMed Web of Science ®Google Scholar
• Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16(2):474–485. doi:10.1158/1078-0432.CCR-09-1322
   PubMed Web of Science ®Google Scholar
• Ahmed N, Salsman VS, Yvon E, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009;17(10):1779–1787. doi:10.1038/mt.2009.133
   PubMed Web of Science ®Google Scholar
• Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y. Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res. 2014;16(3):R61. doi:10.1186/bcr3674
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9:399. doi:10.1126/scitranslmed.aaa0984
   Web of Science ®Google Scholar
• Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–167. doi:10.1038/s41571-019-0297-y
   PubMed Web of Science ®Google Scholar
• Schaft N. The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview. Cancers. 2020;12:9. doi:10.3390/cancers12092567
   Web of Science ®Google Scholar
• Liu C, Qi T, Milner JJ, Lu Y, Cao Y. Speed and Location Both Matter: antigen Stimulus Dynamics Controls CAR-T Cell Response. Front Immunol. 2021;12:748768. doi:10.3389/fimmu.2021.748768
   PubMed Web of Science ®Google Scholar
• Mulazzani M, Frassle SP, von Mucke-heim I, et al. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice. Proc Natl Acad Sci U S A. 2019;116(48):24275–24284. doi:10.1073/pnas.1903854116
   PubMed Web of Science ®Google Scholar
• Leko V, Rosenberg SA. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. Cancer Cell. 2020;38(4):454–472. doi:10.1016/j.ccell.2020.07.013
   PubMed Web of Science ®Google Scholar
• Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35:4. doi:10.1042/BSR20150089
   Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851. doi:10.1038/mt.2010.24
   PubMed Web of Science ®Google Scholar
• Li D, Li X, Zhou WL, et al. Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther. 2019;4:35. doi:10.1038/s41392-019-0070-9
   PubMed Web of Science ®Google Scholar
• Luo F, Qian J, Yang J, et al. Bifunctional alphaHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer. Cell Res. 2016;26(7):850–853. doi:10.1038/cr.2016.81
   PubMed Web of Science ®Google Scholar
• Katz SC, Point GR, Cunetta M, et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 2016;23(5):142–148. doi:10.1038/cgt.2016.14
   PubMed Web of Science ®Google Scholar
• Ding N, Zou Z, Sha H, et al. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat Commun. 2019;10(1):1336. doi:10.1038/s41467-019-09296-6
   PubMed Web of Science ®Google Scholar
• Brown MP, Ebert LM, Gargett T. Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma. Clin Transl Immunol. 2019;8(5):e1050. doi:10.1002/cti2.1050
   PubMed Web of Science ®Google Scholar
• Proshkina G, Deyev S, Ryabova A, et al. DARPin_9-29-Targeted Mini Gold Nanorods Specifically Eliminate HER2-Overexpressing Cancer Cells. ACS Appl Mater Interfaces. 2019;11(38):34645–34651. doi:10.1021/acsami.9b10441
   PubMed Web of Science ®Google Scholar
• Kasaraneni N, Chamoun-Emanuelli AM, Wright G, Chen Z. Retargeting Lentiviruses via SpyCatcher-SpyTag Chemistry for Gene Delivery into Specific Cell Types. mBio. 2017;8:6. doi:10.1128/mBio.01860-17
   Web of Science ®Google Scholar
• Shramova EI, Shilova MV, Ryabova AV, et al. Barnase*Barstar-guided two-step targeting approach for drug delivery to tumor cells in vivo. J Control Release. 2021;340:200–208. doi:10.1016/j.jconrel.2021.11.001
   PubMed Web of Science ®Google Scholar
• Anandappa AJ, Wu CJ, Ott PA. Directing Traffic: how to Effectively Drive T Cells into Tumors. Cancer Discov. 2020;10(2):185–197. doi:10.1158/2159-8290.CD-19-0790
   PubMed Web of Science ®Google Scholar
• Zhang C, Burger MC, Jennewein L, et al. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. J Natl Cancer Inst. 2016;108(5):658. doi:10.1093/jnci/djv375
   Google Scholar
• Merker M, Wagner J, Kreyenberg H, et al. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma. Front Immunol. 2020;11:581468. doi:10.3389/fimmu.2020.581468
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–2664. doi:10.1016/S0140-6736(16)30354-3
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610–621. doi:10.1056/NEJMoa1914510
   PubMed Web of Science ®Google Scholar
• Nadal-Serrano M, Morancho B, Escriva-de-romani S, et al. The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. Cancers. 2020;12:3. doi:10.3390/cancers12030670
   Web of Science ®Google Scholar
• Gradishar WJ. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol. 2013;24(10):2492–2500. doi:10.1093/annonc/mdt217
   PubMed Web of Science ®Google Scholar
• Pegram MD, Miles D, Tsui CK, Zong Y. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors. Clin Cancer Res. 2020;26(4):775–786. doi:10.1158/1078-0432.CCR-18-1976
   PubMed Web of Science ®Google Scholar
• Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol. 2010;17(1):14–17. doi:10.1245/s10434-009-0766-0
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Jeddi-Tehrani M, Golsaz-Shirazi F, et al. A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo. Front Immunol. 2020;11:600883. doi:10.3389/fimmu.2020.600883
   PubMed Web of Science ®Google Scholar
• Lu YJ, Chu H, Wheeler LW, et al. Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies. Front Oncol. 2019;9:151. doi:10.3389/fonc.2019.00151
   PubMed Web of Science ®Google Scholar
• Luo X, Cui H, Cai L, et al. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit. Front Immunol. 2020;11:623. doi:10.3389/fimmu.2020.00623
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Y, Chen K, Qian L, Wang P. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell Int. 2021;21(1):262. doi:10.1186/s12935-021-01972-2
   PubMed Web of Science ®Google Scholar
• NIH; US National Library of Medicine. ClinicialTrials/.gov [homepage]; 2022. Available at: https://www.clinicaltrials.gov/. Accessed July 11, 2022.
   Google Scholar